Chronic Granulomatous Disease

Oncology·MeSH: Bruton type agammaglobulinemia

Prevalence

0.5 / 100K

22 drugs in development·6 companies·6 clinical trials

Drug Pipeline by Phase

Phase 3(5)

Drug	Company
Base-edited hematopoietic stem and progenitor cells	ENANTA PHARMACEUTICALS INC (ENTA)
Peripheral blood stem cells	Filana Therapeutics Inc. (FLNA)
Sirolimus	Filana Therapeutics Inc. (FLNA)
Temsirolimus	Filana Therapeutics Inc. (FLNA)
Tocilizumab	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 2(8)

Drug	Company
Busulfan	ENANTA PHARMACEUTICALS INC (ENTA)
Busulfan	Filana Therapeutics Inc. (FLNA)
Pegfilgrastim	ENANTA PHARMACEUTICALS INC (ENTA)
Plerixafor	ENANTA PHARMACEUTICALS INC (ENTA)
Sirolimus	ENANTA PHARMACEUTICALS INC (ENTA)
Sirolimus	Merus N.V. (MRUS)
Sirolimus	Crinetics Pharmaceuticals, Inc. (CRNX)
Temsirolimus	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1(8)

Drug	Company
Alemtuzumab	Filana Therapeutics Inc. (FLNA)
Busulfan	Crinetics Pharmaceuticals, Inc. (CRNX)
Eltrombopag	Crinetics Pharmaceuticals, Inc. (CRNX)
Filgrastim	ENANTA PHARMACEUTICALS INC (ENTA)
Palifermin	ENANTA PHARMACEUTICALS INC (ENTA)
Palifermin	Merus N.V. (MRUS)
Plerixafor	Merus N.V. (MRUS)
Sirolimus	Structure Therapeutics Inc. (GPCR)

Phase 1/Phase 2(1)

Drug	Company
pm359	Prime Medicine, Inc. (PRME)

BioSniper tracks 22 drugs in development for Chronic Granulomatous Disease across 6 companies.

There are 6 clinical trials targeting Chronic Granulomatous Disease tracked by BioSniper.

The estimated prevalence of Chronic Granulomatous Disease is approximately 0.5 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.